|
**Overview**: Autoimmune Bullous Dermatoses Panel**Introduction**: The Autoimmune Bullous Dermatoses Panel is a diagnostic tool designed to screen for bullous skin disorders using serum samples. In India, autoimmune blistering diseases (pemphigus, bullous pemphigoid) have prevalence ~1-5 per 100,000, with pemphigus vulgaris common in certain communities (anti-desmoglein 1/3 antibodies). Symptoms include blisters, erosions, oral lesions, and pain. High morbidity from underdiagnosis in rural areas, limited dermatology access, overlap with infections, delayed dapsone/steroid therapy leading to sepsis or scarring. Per immunology practices aligned with ICMR and Indian Association of Dermatologists guidelines, the test employs immunoassay for antibody detection over 1-2 days with high sensitivity/specificity, valuable for confirming diagnosis. This diagnostic falls under autoimmune skin screening and targets patients with suspected bullous disorders, addressing accurate detection to guide therapy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing complications. Its serum-based approach ensures reliable detection.**Other Names**: Bullous Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Antibody identification in 1990s; in India, prominence with pemphigus burden.**Purpose**: The test screens for 3 parameters including anti-desmoglein to guide bullous disease diagnosis, confirm autoimmunity, inform treatment.**Test Parameters**: 1. Anti-Desmoglein 1, 2. Anti-Desmoglein 3, 3. Anti-BP180.**Pretest Condition**: No fasting required; patients should report blisters, erosions, oral lesions.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on blister onset, oral involvement, family autoimmune history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated bullous diseases including infection, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent infections can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive antibodies indicate bullous disease, necessitating specialist input. Negative may require follow-up if blisters persist.**Specialist Consultation**: Dermatologists should be consulted for management.**Additional Supporting Tests**: Skin biopsy, DIF for confirmation.**Test Limitations**: May miss early cases; comprehensive approach required.**References**: Indian Journal of Dermatology 2024, Bullous Disease Studies India 2023. |
